OBJECTIVE: To probe into the effects of fluvoxamine combined with risperidone on clinical efficacy

cognitive impairment

positive and negative symptoms and quality of life in patients with schizophrenia. METHODS:Totally 304 patients with schizophrenia admitted into the First Affiliated Hospital of Xi’an Jiaotong University from Sept. 2018 to Dec. 2020 were selected and divided into fluvoxamine group（ 152 cases） and control group（ 152 cases）.The control group was given risperidone orally

while the fluvoxamine group was given Fluvoxamine maleate tablets based on the control group. The clinical efficacy and improvements of negative symptoms

positive symptoms

memory function and quality of life in fluvoxamine group and control group were observed

and the occurrence of adverse drug reactions was recorded. RESULTS: The total effective rate of fluvoxamine group was significantly higher than that of the control group[91. 4%（ 139/152） vs. 80. 9%（ 123/152） ]

with statistically significant difference（ χ2= 7. 072

P =0. 008）. The scores of bizarre behavior in the positive symptom scores of patients in the fluvoxamine group were significantly higher than that in the control group at the 8 th and 10 th weeks after treatment

with statistically significant differences（ P<0. 05）. At the 8 th and 10 th week after treatment

the general negative symptom scores and item scores of apathy

paucity of thought

depressed volition

attention disorder and interest blank of fluvoxamine group were significantly lower than those of the control group

with statistically significant differences（ P < 0. 05）. The scores of Wechsler Memory Scale and World Health Organization Quality of Life Measurements Scale of fluvoxamine group at the8 th and 10 th week after treatment were significantly higher than those of before treatment

and were significantly higher than those of the control group at the same time

with statistically significant differences（ P < 0. 05）. There was no statistical significance in difference in the incidences of adverse drug reactions between patients in the fluvoxamine group and control group [4. 6%（ 7/152） vs. 5. 9%（ 9/152）

χ2= 0. 264

P = 0. 607]. CONCLUSIONS: The combination of fluvoxamine and risperidone can significantly promote the efficacy in the treatment of schizophrenic

improved cognitive impairment and positive and negative symptoms

promote patients’ quality of life without increasing adverse effects.